{"ticker": {"uuid": "6af8de17-73c8-4d19-b709-45778fffd691", "symbol": "NXTG", "name": "Nextage Therapeutics Ltd", "exchange": "TLV", "country": "IL", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Israeli biotech firm Nextage delays earnings report, citing inability to pay auditor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE1QcS1PRVhmN0lXTVBWU1lhVWJYbGRvaUMxeXVRQkxrd1lsOUpkMmZnMzZPNlRwZVNJUzVxcmlHcF83czAwVGJMZFdfZTBpcW41dWk4LUdUdUMydXAwM01xbk9n?oc=5", "source_name": "Ynetnews", "published_at": "2025-08-17T07:00:00+00:00", "published_display": "17 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nextage Therapeutics and Subsidiary IMIO Life Announce Positive Pre- Clinical Toxicity Results for Proprietary Brain Targeting Drug Delivery System", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgJBVV95cUxOTVdvX3A2LVhadk9hQ25VcFY4WENTM0tSSGlRM0N3VEViV3VpTzRvXzRkSnM0NXRqc2lyZ3o3ZzgtMUxmbmlXTUl5c0VwbGVTeVZlMEd1Zkx3ZnZFNktmNEVGejZ5Z0psLTBlT05BbWI3MVZRSnJjQjNzUkcwanVtd19meXRGa3ZkWGVEeEpleElUZGJ6QW9jSG9yUmRWZndwazFlZnl0QjU2RVg3ODdNRnBaSzJXekwwa1NwV1E1SU03bEdSVGtqRFdWdUFwMlZQdjNQS1B2WUo0NmxlUVZKVlF1dVhfbFpxS05uQjdlczRrZFJvcHFTTmtGb2lqWnVycTdyOEtB?oc=5", "source_name": "microdose.buzz", "published_at": "2021-07-13T07:00:00+00:00", "published_display": "13 Jul 2021 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Israeli biotech firm Nextage delays earnings report, citing inability to pay auditor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE1QcS1PRVhmN0lXTVBWU1lhVWJYbGRvaUMxeXVRQkxrd1lsOUpkMmZnMzZPNlRwZVNJUzVxcmlHcF83czAwVGJMZFdfZTBpcW41dWk4LUdUdUMydXAwM01xbk9n?oc=5", "source_name": "Ynetnews", "published_at": "2025-08-17T07:00:00+00:00", "published_display": "17 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nextage Therapeutics and Subsidiary IMIO Life Announce Positive Pre- Clinical Toxicity Results for Proprietary Brain Targeting Drug Delivery System", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgJBVV95cUxOTVdvX3A2LVhadk9hQ25VcFY4WENTM0tSSGlRM0N3VEViV3VpTzRvXzRkSnM0NXRqc2lyZ3o3ZzgtMUxmbmlXTUl5c0VwbGVTeVZlMEd1Zkx3ZnZFNktmNEVGejZ5Z0psLTBlT05BbWI3MVZRSnJjQjNzUkcwanVtd19meXRGa3ZkWGVEeEpleElUZGJ6QW9jSG9yUmRWZndwazFlZnl0QjU2RVg3ODdNRnBaSzJXekwwa1NwV1E1SU03bEdSVGtqRFdWdUFwMlZQdjNQS1B2WUo0NmxlUVZKVlF1dVhfbFpxS05uQjdlczRrZFJvcHFTTmtGb2lqWnVycTdyOEtB?oc=5", "source_name": "microdose.buzz", "published_at": "2021-07-13T07:00:00+00:00", "published_display": "13 Jul 2021 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 50, "total_relevant": 2, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 1, "score": 58, "total": 2, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 75, "events": [{"event": "earnings", "label": "Earnings", "weight": 1.1, "count": 2}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.42, "latest_week": "2026-07-17", "one_week_move": 7.6, "four_week_move": -11.3, "twelve_week_move": -3.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.014822, "market_dynamics_buy_signal": false, "relative_strength": -46.869767, "fair_value_gap": -38.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 35.0843, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.6% over one week, -11.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Ynetnews", "count": 1}, {"label": "microdose.buzz", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 2}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "2", "tone": "neutral", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.6% over one week, -11.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Israeli biotech firm Nextage delays earnings report, citing inability to pay auditor"}], "updated_at": "2026-07-22T01:27:02.491958+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}